Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed refocoxib and meloxicam in general practice in England using prescription-event monitoring data

Rheumatology

Volumn 42, Issue 5, 2003, Pages 622-631

  Layton, Deborah ^a   Heeley, E ^a   Hughes, K ^a   Shakir, S A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Adverse events; COX 2 selective inhibition; Drug safety; Meloxicam; Prescription event monitoring; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; MELOXICAM; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENDER; GENERAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OSTEOARTHRITIS; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; STEADY STATE; UNITED KINGDOM; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL DISEASE; MIDDLE AGED; SEX DIFFERENCE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENGLAND; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PRESCRIPTIONS, DRUG; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SEX FACTORS; SULFONES; THIAZINES; THIAZOLES;

EID: 0042278691     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg141     Document Type: Article

References (46)

1. Raskin JB. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106(5B):3S-12S.
2. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504.
3. Hawkey CJ. The gastroenterologist's caseload: contribution of the rheumatologist. Semin Arthritis Rheum 1997;26(6 Suppl. 1):11-5.
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
5. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum 1997;26(6 Suppl. 1):16-20.
6. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
7. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5-18.
8. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120:594-606.
9. Seibert K, Masferrer JL, Fu JY, Honda A, Raz A, Needleman P. The biochemical and pharmacological manipulation of cellular cyclooxygenase (COX) activity. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A:45-51.
10. Brooks P, Emery P, Evans JF et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999;38:779-88.
11. Kaplan-Machlis B, Klostermeyer BS. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann Pharmacother 1999;33:979-88.
12. Ehrich EW, Dallob A, De Lepeleire I et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
13. Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160:1781-7.
14. Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000; 43:978-87.
15. Hawkey C, Laine L, Simon T et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43:370-7.
16. Laine L, Harper S, Simon T et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.
17. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2.
18. Acevedo E, Castaneda O, Ugaz M et al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand J Rheumatol 2001;30:19-24.
19. Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999;282:1929-33.
20. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003.
21. Noble S, Balfour JA. Meloxicam. Drugs 1996;51:424-30.
22. Panara MR, Renda G, Sciulli MG et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999;290:276-80.
23. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
24. Singh G, Triadafilopoulos G. Meloxicam has a low risk of serious gastrointestinal complications: pooled analysis of 27,039 patients. [Abstact No. OP0085]. European Congress of Rheumatology, Prague: 2001.
25. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.
26. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107(6A):48S-54S.
27. Mann RD. Prescription-event monitoring - recent progress and future horizons. Br J Clin Pharmacol 1998;46:195-201.
28. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000;50:35-42.
29. Layton D, Riley J, Wilton LW, Shakir S. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2003;55:166-74.
30. Mann RD, Rawlins MD, Fletcher P. Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:19-23.
31. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
32. Sweetman S (ed.). Martindale: the complete drug reference. 33rd edn. London: Pharmaceutical Press, 2002.
33. Machin D, Campbell M, Fayers P et al. Sample size tables for clinical studies. Oxford: Blackwell Science, 1997.
34. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998;37:937-45.
35. MacDonald TM, Morant SV, Robinson GC et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. Br Med J 1997;315:1333-7.
36. Lanes S, Garcia Rodriguez LA, Hwang E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiol Drug Saf 2002;9:113-7.
37. Huang JQ, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22.
38. Chan FK, Sung JJ. Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs. Lancet 1998;352:2016.
39. Templeton L, Deehan A, Taylor C, Drummond C, Strang J. Surveying general practitioners: does a low response rate matter? Br J Gen Pract 1997;47:91-4.
40. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001;358:1872-3.
41. McAvoy BR, Kaner EF. General practice postal surveys: a questionnaire too far? Br Med J 1996;313:732-3.
42. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(1 Suppl.):39S-63S.
43. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247-55.
44. Lipsky PE, Abramson SB, Breedveld FC et al. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000; 27:1338-40.
45. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
46. Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981;2:93-4.